Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP501 Combinations in Advanced Pancreatic Cancer
NCT04953962Phase 2Completed
- Sponsor
- CanBas
- Start
- Dec 2021
- Primary completion
- Apr 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CBP-501 in pancreatic cancer (PDAC) (4 arms), sponsored by CanBas. Primary endpoint: Three-month progression free survival rate at 3 months. Started Dec 2021; status: completed.
02
Drugs
CBP-501
03
Conditions
pancreatic cancer (PDAC)
Beyond the preview
Go deeper on NCT04953962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04953962.